Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of "Buy" from Brokerages

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) has been assigned an average recommendation of "Buy" from the seven analysts that are covering the company, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $23.00.

A number of equities analysts have recently issued reports on AURA shares. Scotiabank increased their target price on Aura Biosciences from $20.00 to $23.00 and gave the stock a "sector outperform" rating in a report on Friday, October 18th. Cowen reiterated a "buy" rating on shares of Aura Biosciences in a research report on Friday, October 18th. BTIG Research upped their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a "buy" rating in a report on Friday, October 18th. HC Wainwright raised their price objective on shares of Aura Biosciences from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Friday, October 18th. Finally, Lifesci Capital upgraded Aura Biosciences to a "strong-buy" rating in a research note on Monday, September 9th.

Insider Activity at Aura Biosciences

In related news, insider Los Pinos Elisabet De sold 24,992 shares of the business's stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $12.04, for a total value of $300,903.68. Following the completion of the sale, the insider now directly owns 329,847 shares of the company's stock, valued at $3,971,357.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Aura Biosciences news, CTO Mark Plavsic sold 7,383 shares of Aura Biosciences stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total transaction of $72,722.55. Following the sale, the chief technology officer now directly owns 121,132 shares of the company's stock, valued at approximately $1,193,150.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Los Pinos Elisabet De sold 24,992 shares of the stock in a transaction on Friday, October 18th. The stock was sold at an average price of $12.04, for a total value of $300,903.68. Following the sale, the insider now owns 329,847 shares in the company, valued at $3,971,357.88. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 67,259 shares of company stock worth $780,699. 5.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Aura Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of AURA. Long Focus Capital Management LLC raised its holdings in Aura Biosciences by 113.4% during the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company's stock worth $7,992,000 after purchasing an additional 561,766 shares during the last quarter. Levin Capital Strategies L.P. raised its position in Aura Biosciences by 194.5% in the 2nd quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company's stock valued at $2,476,000 after buying an additional 216,266 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Aura Biosciences by 51.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company's stock worth $1,081,000 after buying an additional 48,549 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Aura Biosciences by 20.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company's stock worth $1,892,000 after purchasing an additional 41,711 shares during the period. Finally, SG Americas Securities LLC bought a new stake in shares of Aura Biosciences in the third quarter valued at $169,000. Institutional investors and hedge funds own 96.75% of the company's stock.

Aura Biosciences Price Performance

Shares of Aura Biosciences stock traded down $0.49 on Tuesday, hitting $10.65. The company had a trading volume of 158,684 shares, compared to its average volume of 175,689. The company has a market cap of $528.35 million, a PE ratio of -5.95 and a beta of 0.33. Aura Biosciences has a 52 week low of $6.63 and a 52 week high of $12.38. The business has a 50-day simple moving average of $9.69 and a 200-day simple moving average of $8.49.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.